Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

GENERIS FARMACEUTICA, SA (508107997), ROCHE FARMACÊUTICA QUIMICA, LDA. (500233810), Alloga Portugal -Armaz.Dist.Farmacêutica (504507230), KRKA FARMACEUTICA

NIF 507981227
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €684,679 33 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €684,679 33 contracts
A2 · Late Publication €1,623,194,286 680 contracts
Contract published to BASE more than 10 days after the signing date
LOW €1,623,194,286 680 contracts
A5 · Threshold Splitting €1,454,277 21 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €1,454,277 21 contracts
A6 · Low Competition €7,791 2 contracts
Only one bidder participated in a competitive procedure
MEDIUM €7,791 2 contracts
A9 · Abnormal Price Reduction €1,879,490,238 545 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €1,879,490,238 545 contracts
C3 · Missing Mandatory Fields €803,891 52 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €803,891 52 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

12
€160,585,953
144
€114,125,933
21
€98,585,733
18
€97,964,660
27
€82,585,958
28
€74,302,565
22
€70,787,374
10
€68,161,178
9
€64,904,351
10
€62,876,190
43
€61,944,745
56
€60,724,793
37
€58,058,552
23
€56,666,068
21
€55,288,381
15
€54,319,127
23
€45,972,115
12
€44,916,386
81
€44,302,949
54
€43,943,970
Page 1 of 3 · 55 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 1 · 2 contracts

Aquisição de ABIRATERONA ORAL 500MG COMP REV ao Lab. Krka para a ULSASI para o ano de 2024
PT · 10584250 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A6 · Low Competition
€7,557 2024-02-26
61/786/2024 - Medicamento Emtricitabina 200 mg + Tenofovir 245 mg Comp
PT · 10701681 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€234 2024-01-12
Overview
Total Value Won
€1,887,220,387
Contracts Won
995
Score 36115 · CRITICAL RISK
NIF
507981227
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • D.R. [P-a1c7]
    Gerente
    since 2020-11-13
  • D.R. [P-a1c7]
    Gerente
    since 2025-01-07
  • L.G. [P-4435]
    Gerente
    since 2020-11-13
  • L.G. [P-4435]
    Gerente
    since 2025-01-07
  • S.J. [P-6513]
    Gerente
    since 2012-06-25
  • S.J. [P-6513]
    Gerente
    since 2022-07-13
  • S.J. [P-6513]
    Gerente
    since 2025-01-07
  • J.C. [P-7000]
    Sócio
    since 2007-02-13
  • B.G. [P-cf60]
    Gerente
    2016-05-02 → 2018-05-16
  • B.K. [P-c5a0]
    Gerente
    until 2020-11-13
  • J.C. [P-7000]
    Gerente
    until 2012-06-25
  • S.K. [P-2a97]
    Gerente
    until 2012-06-25
  • T.S. [P-96c5]
    Gerente
    2018-05-16 → 2020-11-20
  • U.P. [P-c443]
    Gerente
    2012-06-25 → 2016-05-02
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned